Treatment of Small Bowel Neuroendocrine Tumor (NETS): A Single Center's Experience Abstract #385

Introduction: Neuroendocrine tumors (NETS) of the gastrointestinal tract are rare, slow-growing neoplasms. Long-term management of these tumors varies among centers.
Aim(s): To determine if long-term multidisciplinary management at a single center maximizes survival, records from NET patients were reviewed and survival rates were calculated and compared to historical controls.
Materials and methods: The charts of 401 consecutive patients with well-differentiated, small bowel NETS, treated at a collaborative clinic were reviewed. Information relating to the extent of disease and all tumor-related surgeries were collected from the patient records. Kaplan-Meier survival curves were generated, and 5-year, 10-year, and median survival rates were calculated.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Eugene Woltering
Keywords: survival

To read results and conclusion, please login ...

Further abstracts you may be interested in

#594 Neurokinin A Levels Predict Survival in Patients with Well-Differentiated Small Bowel Neuroendocrine Tumors
Introduction: Recent European investigations demonstrated that persistently elevated (> 50 pg/ml) plasma neurokinin A (NKA) levels are associated with poor short-term survival in patients with midgut neuroendocrine tumors (NETS).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Eugene Woltering
#3036 Can Ki-67 with 5.5% Be Better in Predicting Prognosis for Well Differentiated Pancreatic Neuroendocrine Tumors?
Introduction: Pancreatic neuroendocrine tumors (NETs) are rare malignancies, Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis of neuroendocrine tumors. However, the ideal grading method for G1/G2 remains controversial.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Prof. Huang-Ying Tan
Authors: Yuan B, Chen Y Y, Zhang P, Wang X, ...
#386 A Prospective Evaluation of the Effects of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans
Introduction: Proton pump inhibitors (PPIs) are used primarily to treat gastroesophageal reflux disease. PPI-induced achlorhydria increases circulating gastrin and chromogranin A (CGA). CGA is a widely used biomarker for the diagnosis and follow-up for gut-based neuroendocrine tumors (NETs). PPI-induced increases in CGA or gastrin may falsely suggest the presence of a NET when none exists. Pancreastatin, a fragment of CGA, is also commonly used to diagnose and follow NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Eugene Woltering
#1064 Development of Effective Prophylaxis Against Intraoperative Carcinoid Crisis
Introduction: Patients with foregut and midgut neuroendocrine tumors (NETs) can experience life-threatening carcinoid crises during anesthesia. The prophylactic use of a pre-, intra- and post-operative high dose continuous octreotide infusion was evaluated for its ability to prevent carcinoid crises during cytoreductive surgeries.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Surgical treatment
Presenting Author: MD Eugene Woltering
Keywords: carcinoid crisis
#2729 Survival of Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in a Single Institute in North Africa over the Last 16 Years
Introduction: Because of the low incidence, nonspecific symptoms at presentation, lack of awareness, and non-uniform classifications, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) remains a poorly understood disease, and delayed diagnosis is common among patients with GEP-NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Imen Harhira